pubmed.ncbi.nlm.nih.gov

Treatment of post-viral olfactory dysfunction: an evidence-based review with recommendations - PubMed

Review

. 2020 Sep;10(9):1065-1086.

doi: 10.1002/alr.22624. Epub 2020 Jun 25.

Affiliations

Review

Treatment of post-viral olfactory dysfunction: an evidence-based review with recommendations

Nanki Hura et al. Int Forum Allergy Rhinol. 2020 Sep.

Abstract

Background: Post-viral olfactory dysfunction (PVOD) is one of the most common causes of olfactory loss. Despite its prevalence, optimal treatment strategies remain unclear. This article provides a comprehensive review of PVOD treatment options and provides evidence-based recommendations for their use.

Methods: A systematic review of the Medline, Embase, Cochrane, Web of Science, Scopus, and Google Scholar databases was completed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Studies with defined olfactory outcomes of patients treated for PVOD following medical, surgical, acupuncture, or olfactory training interventions were included. The Clinical Practice Guideline Development Manual and Conference on Guideline Standardization (COGS) instrument recommendations were followed in accordance with a previously described, rigorous, iterative process to create an evidence-based review with recommendations.

Results: From 552 initial candidate articles, 36 studies with data for 2183 patients with PVOD were ultimately included. The most common method to assess olfactory outcomes was Sniffin' Sticks. Broad treatment categories included: olfactory training, systemic steroids, topical therapies, a variety of heterogeneous non-steroidal oral medications, and acupuncture.

Conclusion: Based on the available evidence, olfactory training is a recommendation for the treatment of PVOD. The use of short-term systemic and/or topical steroids is an option in select patients after careful consideration of potential risks of oral steroids. Though some pharmacological investigations offer promising preliminary results for systemic and topical medications alike, a paucity of high-quality studies limits the ability to make meaningful evidence-based recommendations for the use of these therapies for the treatment of PVOD.

Keywords: budesonide; evidence-based medicine; olfaction disorders; olfactory training; smell; viral infection.

© 2020 ARS-AAOA, LLC.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1

PRISMA flow diagram. PRISMA = Preferred Reporting Items for Systematic Reviews and Metaanalyses.

Similar articles

Cited by

References

    1. Van Regemorter V, Hummel T, Rosenzweig F, et al. Mechanisms linking olfactory impairment and risk of mortality. Front Neurosci. 2020;14:140 - PMC - PubMed
    1. Kohli P, Soler ZM, Nguyen SA, et al. The association between olfaction and depression: a systematic review. Chem Senses. 2016;41(6):479‐486. - PMC - PubMed
    1. Pinto JM, Wroblewski KE, Kern DW, et al. Olfactory dysfunction predicts 5‐year mortality in older adults. PLoS One. 2014;9(10):e107541. - PMC - PubMed
    1. Hummel T, Whitcroft KL, Andrews P, et al. Position paper on olfactory dysfunction. Rhinology. 2017;54:1‐30. - PubMed
    1. Deems DA, Doty RL, Settle G, et al. Smell and taste disorders, a study of 750 patients from the University of Pennsylvania Smell and Taste Center. Arch Otolaryngol Neck Surg. 1991;117(5):519‐528. - PubMed

Publication types

MeSH terms

Substances